US Bancorp
NGNE icon

US Bancorp’s Neurogene NGNE Stock Holding History

US Bancorp’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.62K Buy
147
+117
+390% +$3.22K ﹤0.01% 3679
2026
Q1 		$605 Sell
30
-133
-82% -$2.58K ﹤0.01% 3987
2025
Q4 		$3.36K Buy
163
+152
+1,382% +$3.78K ﹤0.01% 3645
2025
Q3 		$191 Hold
11
– – ﹤0.01% 3948
2025
Q2 		$164 Hold
11
– – ﹤0.01% 4088
2025
Q1 		$129 Sell
11
-32
-74% -$556 ﹤0.01% 4131
2024
Q4 		$983 Sell
43
-69
-62% -$2.57K ﹤0.01% 3958
2024
Q3 		$4.7K Sell
112
-13
-10% -$504 ﹤0.01% 3588
2024
Q2 		$4.55K Buy
+125
New +$4.41K ﹤0.01% 3548
2024
Q1 		– Sell
-3,467
Closed -$67.2K – 4056
2023
Q4 		$67.2K Hold
3,467
– – ﹤0.01% 2518
2023
Q3 		$54.8K Buy
3,467
+1,250
+56% +$18.5K ﹤0.01% 2400
2023
Q2 		$36.8K Hold
2,217
– – ﹤0.01% 2664
2023
Q1 		$31K Buy
2,217
+1,167
+111% +$13.7K ﹤0.01% 2755
2022
Q4 		$10.7K Hold
1,050
– – ﹤0.01% 3278
2022
Q3 		$13K Hold
1,050
– – ﹤0.01% 3271
2022
Q2 		$22K Buy
1,050
+500
+91% +$12.2K ﹤0.01% 2999
2022
Q1 		$21K Buy
+550
New +$32.1K ﹤0.01% 3046
2021
Q4 		– Sell
-8
Closed -$1K – 4188
2021
Q3 		$1K Buy
+8
New +$1.23K ﹤0.01% 3993

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

US Bancorp's NGNE Position: Q2 2026 in Review

US Bancorp increased its Neurogene (NGNE) stake by 390% in Q2 2026, buying an estimated $3.22K and bringing the position to 147 shares worth $4.62K. The position accounts for ﹤0.01% of the portfolio, ranked #3679.

US Bancorp first reported a position in NGNE in Q3 2021 and has held it in 18 quarters since. The position peaked at $67.2K in Q4 2023. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • US Bancorp held 147 shares of Neurogene worth $4.62K as of Q2 2026.
  • US Bancorp bought 117 Neurogene shares in Q2 2026, an estimated $3.22K.
  • Neurogene made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3679 holding.
  • US Bancorp first reported a position in Neurogene in Q3 2021 and has held it in 18 quarters since.
  • US Bancorp's Neurogene position peaked at $67.2K in Q4 2023.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.